OTCMKTS:GNHAY Vifor Pharma (GNHAY) Stock Price, News & Analysis → FW: 234x Gain (From Weiss Ratings) (Ad) Free GNHAY Stock Alerts $38.39 0.00 (0.00%) (As of 01/12/2023) Add Compare Share Share Today's Range$38.39▼$38.3950-Day Range$38.39▼$38.3952-Week Range$31.18▼$38.39VolumeN/AAverage Volume7,364 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Vifor Pharma alerts: Email Address Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Vifor Pharma Stock (OTCMKTS:GNHAY)Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of August 9, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.Read More GNHAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNHAY Stock News HeadlinesOctober 12, 2022 | finance.yahoo.comApproval of delisting of Vifor Pharma AG's registered sharesAugust 20, 2022 | seekingalpha.comCara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patientsMay 4, 2024 | Behind the Markets (Ad)Investors Alert: The Next Big Thing in Weight LossUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.August 19, 2022 | seekingalpha.comVifor Fresenius' rare autoimmune disease drug Tavneos gets UK NICE backingJune 20, 2022 | nasdaq.comEuropean Commission Commences Antitrust Investigation Against Vifor PharmaJune 20, 2022 | uk.finance.yahoo.comEU regulators investigate Vifor Pharma over anti-competitive behaviourJune 20, 2022 | marketwatch.comVifor Pharma Faces EU Antitrust InvestigationJune 20, 2022 | finance.yahoo.comEU antitrust regulators to probe if Vifor Pharma disparages rivalMay 4, 2024 | Behind the Markets (Ad)Investors Alert: The Next Big Thing in Weight LossUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.May 12, 2022 | finance.yahoo.comUpdate on the timeline for Vifor Pharma tender offerApril 26, 2022 | finance.yahoo.com94th Vifor Pharma Group Annual General MeetingApril 2, 2022 | apnews.comAmerican Kidney Fund Announces Support from Vifor Pharma for Pruritus Education CampaignMarch 3, 2022 | finance.yahoo.comPublication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percentFebruary 22, 2022 | finance.yahoo.comAkebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat LaunchFebruary 2, 2022 | finance.yahoo.comVifor Pharma appoints two new members to the Executive CommitteeFebruary 1, 2022 | benzinga.comCordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor PharmaJanuary 19, 2022 | finance.yahoo.comVFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitisJanuary 18, 2022 | finance.yahoo.comCSL BEHRING AG PUBLISHES OFFER PROSPECTUS ON PUBLIC TENDER OFFER FOR ALL PUBLICLY HELD SHARES OF VIFOR PHARMA LTD.December 20, 2021 | businesswire.comVifor Pharma and American Regent announce settlement of Injectafer ® patent litigationDecember 16, 2021 | finance.yahoo.comVifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharmaDecember 14, 2021 | benzinga.comCSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021December 14, 2021 | marketwatch.comVifor Pharma Surges Again as Board Recommends CSL Bid Valuing Equity at $11.7 BlnDecember 14, 2021 | businesswire.comCSL Limited announces tender offer to acquire Vifor Pharma LtdDecember 14, 2021 | afr.comCSL stalked Vifor Pharma for a decadeDecember 14, 2021 | afr.comCSL buys Vifor Pharma in $16.4b dealDecember 10, 2021 | finanznachrichten.deVifor Pharma: First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell diseaseDecember 10, 2021 | finance.yahoo.comFirst patient enrolled in phase-IIa study of vamifeport in patients with sickle cell diseaseSee More Headlines Receive GNHAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vifor Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:GNHAY CUSIPN/A CIKN/A Webwww.viforpharma.com Phone(158) 851-8000FaxN/AEmployees2,200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Alexandros SigalasActing CFO & Head of IT & Admin.Mr. Frederic ZwahlenHead of Technical OperationsMr. Julien VignotHead of Investor Relations & TreasuryDr. Oliver P. KronenbergGroup Gen. CounselMs. Nathalie PonnierGlobal Head Corp. CommunicationsMr. Michael Puri (Age 54)Chief HR Officer Dr. Christoph Springer (Age 55)Chief Strategy Officer Dr. Thomas KasparHead of Global Quality ManagementDr. Thierry TeilHead of Global Medical AffairsMs. Carolina PonchioneHead of Exec. Search & Employer BrandingMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors GNHAY Stock Analysis - Frequently Asked Questions How have GNHAY shares performed in 2024? Vifor Pharma's stock was trading at $38.3850 at the start of the year. Since then, GNHAY stock has increased by 0.0% and is now trading at $38.3850. View the best growth stocks for 2024 here. How do I buy shares of Vifor Pharma? Shares of GNHAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GNHAY) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe asset beating inflation by 4xColonial MetalsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceWarren Buffet Stockpiling Gold?Reagan Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vifor Pharma AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.